The India contract development and manufacturing organization (CDMO) market was valued at USD 25.51 Billion in 2025 driven by large pool of skilled scientists, cost-effective manufacturing capabilities, and a well-established generic and biosimilars industry across the region. It is expected to grow at a CAGR of 10.80% during the forecast period of 2026-2035 and attain a market value of USD 71.14 Billion by 2035. In addition, the rising demand for complex biologics, global expansion strategies by Indian CDMOs, and increasing collaborations are driven by regulatory alignment with major markets like the U.S. and EU.
Indian CDMOs benefit from a long history in generic drug manufacturing, which has shaped a workforce skilled in process optimization, scale-up, and regulatory compliance. That foundation is now being applied to more advanced services, including biologics, cell and gene therapies, and niche formulations like antibody-drug conjugates (ADCs). As global demand for these therapies grows, Indian firms are investing in high-containment facilities, single-use bioreactors, and integrated R&D platforms to support the shift.
Base Year
Historical Period
Forecast Period
India’s expanding biologics capabilities are attracting global pharmaceutical firms seeking cost-effective, high-quality development and manufacturing partnerships.
The market growth is driven by the rising demand for oncology and specialty drug outsourcing, driving investment in India’s advanced therapeutic manufacturing infrastructure.
One of the major market trends include rising government support and regulatory harmonization, enhancing India’s global appeal as a reliable and scalable CDMO destination.
Compound Annual Growth Rate
10.8%
Value in USD Billion
2026-2035
*this image is indicative*
Contract development and manufacturing organizations (CDMOs) play a vital role in India's pharmaceutical and medical device industries by offering end-to-end services from research and development to commercial-scale manufacturing. They enable companies to reduce operational costs, accelerate product development, and comply with stringent global regulatory standards. With India's strong manufacturing capabilities, skilled workforce, and supportive policies, CDMOs attract both domestic and international clients. Their presence enhances innovation, efficiency, and global competitiveness, significantly contributing to the growth of India’s life sciences sector. The market is expected to grow at a CAGR of 10.80% during the forecast period of 2026-2035 and attain a market value of USD 71.14 Billion by 2035.
Programs Based on Strengthening India’s Clinical Research and CDMO Capabilities to Boost Market Growth
In February 2025, Avance Clinical, an Australian CRO, established a specialized biometrics hub in Bangalore to enhance its GlobalReady program. This expansion focuses on statistical programming and data analytics to accelerate early-phase clinical trials for biotech companies in the United States and Australia. As demand for outsourced clinical research rises and India remains a hub for skilled talent and cost-effective services, this move is expected to elevate India’s global standing in the CRO and CDMO markets during the forecast period.
Biologics Manufacturing Advancements to Meet Rising India Contract Development and Manufacturing Organization (CDMO) Market Demand
In January 2025, Shilpa Biologicals inaugurated a new bioconjugation manufacturing facility in Karnataka (a Southern state in India), joining the global league of CDMOs offering integrated antibody-drug conjugate (ADC) capabilities. This complements its existing cytotoxic fill-finish site in Hyderabad and positions India as a growing hub for complex biologics manufacturing. With increasing demand for high-quality, cost-efficient biologics production, such infrastructure upgrades are expected to attract international partnerships and boost the growth and global competitiveness of India’s CDMO market.
The major market trends in the Indian CDMO market include rising global acquisitions and hybrid manufacturing models, enhancing value and development of the market.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
Market Breakup by Application
Market Breakup by Region
Oncological Diseases to Lead the Market Share by Application
Oncological diseases are projected to hold the largest market share in India's contract development and manufacturing organization (CDMO) sector due to the escalating cancer burden and the growing demand for advanced therapeutics. In 2022, India reported approximately 1.46 million new cancer cases, with projections indicating an increase to 1.57 million by 2025, reflecting a 12.8% rise over five years. This surge underscores the urgent need for innovative cancer treatments. India’s robust capabilities in developing and manufacturing complex generics, biosimilars, and antibody-drug conjugates attract global pharmaceutical companies seeking cost-effective oncology drug development. As per the analysis by Expert Market Research, the India biosimilar market is expected to grow at a CAGR of 14.20% during the forecast period of 2025-2034. In contrast, while cardiovascular and infectious diseases also contribute significantly, the complexity, investment, and innovation in oncology drug pipelines continue to drive the segment’s dominance through the forecast period.
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Established in 1993 and headquartered in Bangalore, India, Syngene International Limited is a leading contract research, development, and manufacturing organization (CRDMO). It offers integrated services across the drug development value chain, including discovery chemistry, biology, safety assessment, and commercial manufacturing. Syngene caters to global pharmaceutical, biotechnology, and agrochemical companies. Its state-of-the-art facilities and collaborations with major multinationals such as Bristol Myers Squibb reinforce its position as a key player in India’s CDMO ecosystem.
Piramal Pharma Ltd., headquartered in Mumbai and established in 1988, is a global pharmaceutical company offering end-to-end contract development and manufacturing services. Through its CDMO division, Piramal Pharma Solutions, it supports drug substance and drug product development for small and large molecules. The company’s portfolio spans clinical trial supply, API manufacturing, and sterile fill-finish. With facilities across North America, Europe, and India, Piramal is recognized for its regulatory compliance and scalable manufacturing capabilities.
Founded in 1990 and headquartered in Hyderabad, Divi’s Laboratories Ltd. is one of India’s largest pharmaceutical manufacturing firms, focused on APIs, intermediates, and custom synthesis. With strong capabilities in complex chemistry and large-scale production, Divi’s serves leading global pharma companies as a trusted CDMO partner. The company operates world-class manufacturing facilities and maintains high compliance with international regulatory standards, making it a major contributor to India’s prominence in outsourced pharmaceutical development.
Laurus Synthesis Private Limited, a subsidiary of Laurus Labs headquartered in Hyderabad and established in 2022, offers specialized contract research and manufacturing services. It focuses on custom synthesis, process development, and manufacturing of niche APIs and intermediates. With capabilities in high-potency APIs and complex chemistry, Laurus Synthesis supports early to late-stage development for pharmaceutical companies. The company’s scientific expertise, regulatory focus, and modern infrastructure position it as a rising player in India’s CDMO landscape.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Jubilant Pharmova Limited Company, Thermo Fisher Scientific Inc. (Patheon Pharma Services), Lonza Group AG, WuXi STA, AGC Biologics, Pfizer, Inc., and PCI Pharma Services.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Service Type |
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share